Humasis, Up 6.39% on Rising Theme of COVID-19 (Diagnosis/Treatment/Vaccine Development, etc.)

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while Humasis, a related stock attracting attention, surged by 6.39% compared to the previous day. Humasis is known as an in vitro diagnostic device company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Humasis’s quant financial score was 10.99 points, ranking 29th in the quant financial ranking within the COVID-19 (diagnosis/treatment/vaccine development, etc.) related theme. This can be interpreted as Humasis having relatively low investment attractiveness from a financial perspective. On the other hand, United Pharmaceutical ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.